Status: Not yet recruiting
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
This is an open label, intra-patient dose escalation, to evaluate ADI-PEG 20, in combination with Temozolomide (TMZ) and radiation therapy (RT) in children, adolescents and young adult patients with newly diagnosed high grade glioma (HGG).
Participants needed: 97
Trial details
Phase: Phase 1, Phase 2Age: 3-39Biological sex: AllType: InterventionalSponsor: Sabine Mueller, MD, PhDUpdated: Feb 5, 2026Locations: 1
Eligibility criteria
Participants must have histologically and molecularly confirmed newly diagnosed... [+21]
Participants who have received any systemic therapy or RT, including any investi... [+7]